PDSB Trading Analysis - 10/02/2026 03:15 PM — TRU-SENTIMENT

PDSB (PDS Biotechnology Corporation Common Stock) at $0.74. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $140 vs put $0. RSI 67.6.

TRU-SENTIMENT · DeltaNeutral

PDSB Trading Analysis - 10/02/2026 03:15 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

PDSB (PDS Biotechnology Corporation Common Stock) at $0.74. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $140 vs put $0. RSI 67.6.

Symbol
PDSB
Price
$0.74
Article bias (separate from True Sentiment)
neutral
Conviction
medium
Published
2026-10-02 15:15:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis—Delta 40–60 Options:

Call dollar volume: $140.00 (100.00%)
Put dollar volume: $0.00 (0.00%)
Total directional dollar volume: $140.00

Key Statistics: PDSB

$0.74 +3.33%
52-Week Range
$0.20 - $1.55
Market Cap
$53.59M
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
1.11
Next Earnings
N/A
Avg Volume
$20.78M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

EPS (trailing 12 mo)$-0.64
Market cap$53.59M
Shares outstanding72.5M

Dividend

Dividend yield0.00%

Risk & range

Beta1.11
52-week low$0.20
52-week high$1.55
Historical volatility234.6%

Ownership & trading

Institutional ownership5.3%
Average daily volume69.0M sh

Reported figures; no analyst estimates.


📈 Analysis

PDSB Stock Analysis

Data timestamp: October 2, 2026, with the latest completed daily close at $0.72 and the latest supplied intrabar at $0.74.

PDSB remains a highly speculative, loss-making biotech following an extraordinary September price spike. Momentum indicators are mixed: the MACD and longer moving averages remain positive, while the recent pullback, declining short-term price action, and overbought RSI show that volatility and retracement risk remain substantial.

News Headlines & Context:

News-data limitation: The embedded dataset contains no company announcements, clinical updates, earnings releases, regulatory decisions, or verified news-feed headlines. No October 2026 headline can therefore be confirmed without inventing information.
  • Clinical-development context: General company context identifies Praxis Precision Drugs as a clinical-stage biotechnology company whose valuation can be highly sensitive to trial results, regulatory milestones, safety findings, and clinical timelines. No current trial result is included in the supplied data.
  • September volatility catalyst: The embedded price history shows a surge from a $0.22 close on September 4 to a $1.06 intraday high on September 16, followed by a retreat to $0.72 by October 1. This indicates that speculative repositioning or event-driven trading may have materially distorted the prior price base.
  • Fundamental risk context: Trailing EPS is negative $0.64, no P/E is available, and key financial fields—including revenue, margins, debt, cash flow, and analyst targets—are missing. That absence of reported operating data is itself a major biotech risk.
  • Current catalyst gap: The supplied files contain no earnings date, FDA decision date, trial readout date, financing announcement, or partnership update with which to confirm an upcoming catalyst.

News context is separate from the data-driven analysis below. The technical data show a post-spike correction rather than a confirmed fundamental revaluation.

Fundamental Analysis:

MetricPDSB DataInterpretation
Trailing EPS-$0.64The company is not profitable on a trailing basis.
Trailing P/ENot availableNegative EPS makes a conventional P/E meaningless.
Forward P/ENot availableNo forward earnings estimate is supplied.
PEG ratioNot availableNo sector or peer PEG comparison can be made from the dataset.
Market capitalization$53.59MSmall capitalization increases liquidity, dilution, and volatility risk.
Shares outstanding72.47MLarge share count relative to market value is consistent with a highly speculative equity.
Dividend yield0.00%No income support is present.
Institutional ownership5.31%Relatively limited institutional participation may amplify price moves.
Average volume69.00MElevated turnover reflects the post-spike speculative period, though average volume is not directly comparable with the latest session.
Beta1.11Moderately positive market sensitivity, but PDSB’s company-specific volatility is much higher.
Historical volatility234.64%Extreme volatility makes normal valuation and technical signals less reliable.

Operating Performance

  • Revenue growth: Total revenue and YoY growth are not provided, so no revenue trend can be verified.
  • Gross, operating, and net margins: All are unavailable. The negative trailing EPS nevertheless confirms that the company is currently loss-making on this measure.
  • Debt-to-equity: Not provided; balance-sheet leverage cannot be assessed.
  • Return on equity: Not provided.
  • Free cash flow: Not provided, preventing an assessment of cash burn and financing dependence.
  • Analyst consensus: No analyst recommendation, target price, or opinion count is supplied.
Fundamental risk alert: Negative earnings, a $53.59M market capitalization, 234.64% historical volatility, and missing balance-sheet and cash-flow data materially weaken the investment case. The technical bullish signals should not be interpreted as evidence of improving financial fundamentals.

Current Market Position:

Latest completed close
$0.72
Latest intrabar
$0.74
October 1 change
-2.52%
Five-session close change
-11.33%
From $1.06 30-day high
-30.09%
From September 16 close
-27.76%

The latest completed close of $0.72 was down 2.52% from $0.73 on September 30. The stock declined from a $0.81 close on September 25, while the October 1 session reached a high of $0.76 and a low of $0.70.

On October 2, the latest supplied intrabar recovered to $0.74 from a recent intraday low of $0.73. That rebound improved the final observed price by approximately 1.80% from the recent intraday low, but the stock remained roughly 1.20% below the October 2 opening price of $0.75.

The broader structure remains corrective: PDSB closed approximately 30.09% below its $1.06 30-day high and 27.76% below the September 16 close of $0.99.

Technical Analysis:

Technical Indicators

RSI (14)
67.62
MACD
$0.10
MACD Signal
$0.08
MACD Histogram
$0.02
5-Day SMA
$0.75
20-Day SMA
$0.62
50-Day SMA
$0.51
ATR (14)
$0.15

Interactive charts load with JavaScript. This text is the crawlable summary.